Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14359569 | 0.92 | SLC6A2 (0.45) | SLC6A2SLC6A3SLC6A4DPP7 | |
| SCHEMBL20960624 | 0.92 | SLC6A2 (0.45) | SLC6A2SLC6A3SLC6A4DPP7 | |
| SCHEMBL12965781 | 0.87 | SLC6A2 (0.42) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL26725297 | 0.87 | SLC6A2 (0.42) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL21846836 | 0.85 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4DPP7 | |
| SCHEMBL4035790 | 0.82 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4038090 | 0.82 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL21567213 | 0.81 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL20841352 | 0.80 | SLC6A2 (0.48) | SLC6A2SLC6A3SLC6A4DPP7 | |
| SCHEMBL12323874 | 0.79 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3246034-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | Anacor Pharmaceuticals, Inc. (US) | 2017-11-22 | — | — | EP | disclosed |
| CN-101010130-A | Ionic polymer membranes | BP CORP NORTH AMERICA INC (US) | 2007-08-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | SLC6A2 4822/4885SLC6A3 4776/4885SLC6A4 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.